Propofol pretreatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test

Psychiatry Research

Volumn 185, Issue 1-2, 2011, Pages 248-253

  Wang, Xiaobin ^a   Yang, Yilin ^a   Zhou, Xian ^a   Wu, Jiali ^a   Li, Jiali ^b   Jiang, Xian ^a   Qu, Qiang ^a   Ou, Cehua ^a   Liu, Li ^a   Zhou, Shuzhi ^a  

^a THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

AMPA; BDNF; Depression; Ketamine; Propofol; Swim test

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; PROPOFOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INTERACTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIMMING TEST; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; KETAMINE; MALE; PROPOFOL; RATS; RATS, WISTAR; RECEPTORS, AMPA; SWIMMING;

EID: 78650227581     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.046     Document Type: Article

References (31)

1. Banke T.G., Bowie D., Lee H.K., Huganir R.L., Schousboe A., Traynelis S.F. Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. Journal of Neuroscience 2000, 20:89-102.
2. Berman R.B., Cappielo A., Anand A., Oren D.A., George R.H., Charney D.S. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
3. Britt G.C., McCance-Katz E.F. A brief overview of the clinical pharmacology of "club drugs". Substance Use & Misuse 2005, 40:1189-1201.
4. Chaturvedi H.K., Bapna J.S., Chandra D. Effect of fluvoxamine and N-methyl-d-aspartate receptor antagonists on shock-induced depression in mice. Indian Journal of Physiology Pharmacology 2001, 45:199-207.
5. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
6. Du J., Suzuki K., Wei Y., Wang Y., Blumenthal R., Chen Z. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007, 32:793-802.
7. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorder. Biological Psychiatry 2006, 59:1116-1127.
8. Dybała M., Siwek A., Poleszak E., Pilc A., Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. Journal of Neural Transmission 2008, 115:1519-1520.
9. Engin E., Treit D., Dickson C.T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009, 161:359-369.
10. Eiji Shimizu, Kenji Hashimoto, Naoe Okamura Alterations of Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Depressed Patients with or without Antidepressants. Biological Psychiatry 2003, 54:70-75.
11. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Science 2006, 79:281-286.
12. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Barbosa L.M., Andreazza A.C. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacology Biological Psychiatry 2008, 32:140-144.
13. Gardier A.M. Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor. Behavioural Pharmacology 2009, 20:18-32.
14. Haines M., Mao L.M., Yang L., Arora A., Fibuch E.E., Wang J.Q. Modulation of AMPA receptor GluR1 subunit phosphorylation in neurons by the intravenous anaesthetic propofol. British Journal of Anaesthesia 2008, 100:676-682.
15. Hunt M.J., Rainaud B., Garcia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens freely moving rats. Biological Psychiatry 2006, 60:1206-1214.
16. Karege F., Perret G., Bondolfi G. Decreased serum brain-derived neurotrophic factor levels in major depressed patients[J]. Psychiatry Research 2002, 109:143-148.
17. Klaus Krampfl, Cordes Anna-Lena, Schlesinger Friedrich, Wolfes Heiner, Bufler Johannes Effects of propofol on recombinant AMPA receptor channels. European Journal of Pharmacology 2005, 51:11-17.
18. Kos T., Popik P., Pietraszek M., Schafer D., Danysz W. Dravolina, O., Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol 2006, 16:297-310.
19. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 2008, 63:349-352.
20. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports 2007, 9:467-474.
21. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Joural of Neuroscience 1997, 17:2921-2927.
22. Oh M.C., Derkach V.A., Guire E.S., Soderling T.R. Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation. Journal of Biological Chemistry 2006, 281:752-758.
23. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatment. Nature 1977, 266:730-732.
24. Roche K.W., O'Brien R.J. Mammen AL, Bernhardt J, Huganir RL. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 1996, 16:1179-1188.
25. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7:426-437.
26. Sanjay J., Husseini K., Dennis S. Novel Drugs and Therapeutic Targets for Severe Mood Disorders. Neuropsychopharmacology 2008, 33:2080-2092.
27. Sinner B., Graf B.M. Ketamine. Handbook of Experimental Pharmacology 2008, 182:313-333.
28. Siuciak J.A., Lewis D.R. Wiegand SJ. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacology Biochemistry and Behavior 1997, 56:131-137.
29. Yejun Zhao, Lena Sun Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. Journal of Clinical Neuroscience 2008, 15:1264-1269.
30. Yuluǧ B., Ozan E., Gönül A.S., Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Research Bull 2009, 78:267-269.
31. Zarate C.A., Singh J.B., Carson P.J., Brutshe N.E., Ameli R., Luckenbaugh D.A. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.